ABT

Abbott Laboratories Q1 2004 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2004. Abbott Laboratories is a global healthcare company engaged in the discovery, development, manufacture, and sale of health care products. The reporting period includes significant corporate restructuring activities, specifically the announced spin-off of its core hospital products business into a new entity, Hospira, Inc., and major acquisitions in the diagnostics sector.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13.9% year-over-year, driven by unit growth and a weaker U.S. dollar which positively impacted sales by 4.9%.
• Segment Performance: Pharmaceutical Products sales rose 24.4% (driven by Flomax, Synthroid, Tricor, and Humira). International sales grew 19.0%. Ross Products increased 10.9%.
• Acquisitions: Abbott acquired i-STAT Corporation for approximately $394 million in January 2004, recording a $60 million charge for in-process R&D. In April 2004, Abbott acquired TheraSense, Inc. for approximately $1.2 billion.
• Expense Increases: Selling, general, and administrative expenses rose 21.9% due to marketing support for new products like Humira. R&D expenses increased 5.7%.
• Debt Structure: Long-term debt increased significantly due to the issuance of $1.5 billion in new debt (maturing 2009-2014) to fund the TheraSense acquisition and reduce commercial paper borrowings.

Guidance, Outlook, and Risks

• Hospira Spin-off: Abbott announced a special dividend distribution of Hospira, Inc. stock to shareholders (1 share of Hospira for every 10 shares of Abbott). The distribution is expected on April 30, 2004. Hospira will assume approximately $700 million of debt. Future financial results for Hospira will be reported as discontinued operations.
• Product Outlook: Worldwide sales of Humira totaled $149 million in Q1 2004 and are forecasted to exceed $700 million for the full year 2004.
• Tax Rate: The effective tax rate for Q1 2004 was 25.8%, increased from 24.5% due to non-deductible R&D charges from the i-STAT acquisition. Management anticipates the rate for the rest of 2004 will be higher than 24.5% due to the TheraSense acquisition.
• Litigation: Abbott is involved in various antitrust suits regarding prescription drug pricing, patent disputes (Depakote, Biaxin), and product liability claims (OxyContin, Meridia, Lupron). Management estimates a range of possible loss for legal and environmental matters between $120 million and $200 million, with $135 million currently reserved.
• Share Repurchases: Abbott purchased 6.9 million shares of common stock in Q1 2004 at a cost of $297 million. Approximately 4.8 million shares remain available for purchase under the current authorization.

Investor Verification Checklist

• Verify the final terms and timing of the Hospira spin-off and the specific assets/liabilities retained by Abbott versus transferred to Hospira.
• Confirm the integration progress and financial impact of the TheraSense and i-STAT acquisitions, including the final valuation of goodwill and intangible assets.
• Monitor the status of pending antitrust litigation and product liability lawsuits, specifically regarding OxyContin and Lupron, to assess potential changes in the $135 million reserve.
• Review the impact of the weaker U.S. dollar on future international revenue projections versus organic growth.
• Track the effective tax rate for subsequent quarters to confirm the impact of non-deductible acquisition-related charges.